mp.weixin.qq.com· 医麦创新药·· 3 hours agoPickScore59
Alcon Acquires MacTel Cell Therapy ENCELTO for $550 Million
5.5 亿美元！首个 MacTel 细胞治疗药物被收购
In brief
Alcon has acquired ENCELTO (revakinagene taroretcel-lwey) for $550 million and added it to its retinal product portfolio. ENCELTO is the first and only FDA-approved therapy for idiopathic macular telangiectasia type 2 (MacTel) in adults; before its approval, no FDA-approved treatment for MacTel existed.
Why it matters
The $550 million deal brings the FDA-approved MacTel cell therapy into Alcon's retinal portfolio, noting no approved therapy existed before.
Source: mp.weixin.qq.com · mp.weixin.qq.com